ATRA (Atara Bio) חוב לטווח קצר להון

Atara Biotherapeutics (ATRA) develops advanced methods for combating oncology and autoimmune disorders. This daily price chart confirms the technological superiority of the Ebvallo platform within the biotechnology sector. Revenue is generated through the supply of high-cost cell therapies to specialized clinics and insurance structures. The current figure stands at 0.00. Competitiveness is sustained by patents for multiple sclerosis therapy, despite significant research and development expenditures.

This ratio measures the proportion of short-term liabilities relative to equity, determining the company's dependence on rapid liquidity and the risk of default. By analyzing the short-term liabilities-to-equity ratio, an investor assesses the balance between financial stability and expansion rates, which is critical for Atara Biotherapeutics (ATRA) during the market launch of Ebvallo and the scaling of allogeneic T-cell therapies.